Table 5 Differences in the clinical characteristics of the population according to median levels of admission hsTnT.

From: The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome

Variable

N

Admission hs Troponin

P-Value

Below the median

Above the median

Age, years

200

59 (13)

78 (11)

 < 0.001

Male sex, n (%)

200

39 (38)

30 (31)

0.302

Current smoking, %

187

4 (4)

2 (2)

0.494

PaO2*

182

77 (63–87)

61 (50–74)

 < 0.001

PaO2/FiO2*

194

300 (240–371)

257 (195–324)

0.001

Glucose, mg/dL

194

121 (34)

148 (72)

 < 0.001

Haemoglobin, g/dl*

195

14 (12.7–14.9)

12.9 (11.4–14.6)

0.006

Leukocyte count, cells/μl*

197

6380(4780–8330)

6690(5240–10,060)

0.079

Lymphocyte count, cells/μl*

197

1100 (690–1330)

835 (540–1116)

 < 0.001

Neutrophils count, cells/μl*

194

4500 (3120–6240)

5600 (3447–7665)

0.036

Platelets count, cells/μl*

197

196 (149–248)

175 (129–238)

0.126

INR*

193

1.21 (1.13–1.28)

1.25 (1.18–1.48)

0.002

Total Bilirubin, mg/dL*

194

0.44 (0.32–0.63)

0.56 (0.38–0.76)

0.038

Aspartate transaminase, U/L*

186

32 (24–50)

34 (25–51)

0.737

Alanine transaminase, U/L*

195

33 (23–49)

22 (14–36)

 < 0.001

Creatinine, mg/dL*

195

0.89 (0.78–1.03)

1.24 (0.96–1.83)

 < 0.001

Sodium, mEq/L*

196

138 (135–140)

138(134–141)

0.467

Potassium, mEq/L*

192

3.98 (3.73–4.25)

4.13 (3.84–4.47)

0.007

D-dimer, mg/L*

75

0.32 (0.21–0.69)

0.67 (0.35–1.10)

0.021

Lactate Dehydrogenase, U/L*

109

283 (216–405)

357 (251–467)

0.039

Creatine phosphokinase, U/L*

100

76 (50–213)

92 (56–207)

0.587

High sensitivity troponin T, ng/L*

200

9 (6–12)

41 (26–85)

 < 0.001

Procalcitonin, ng/mL*

177

0.08 (0.05–0.16)

0.19 (0.10–0.65)

 < 0.001

C-reactive protein, mg/dl*

193

4.31 (1.79–10.67)

8.88 (4.87–18.49)

 < 0.001

Comorbidities

 Chronic obstructive pulmonary disease, n (%)

200

4 (4)

23 (24)

 < 0.001

 Asthma, n (%)

199

8 (8)

4 (4)

0.286

 Diabetes mellitus, n (%)

200

9 (9)

29 (30)

 < 0.001

 Arterial hypertension, n (%)

200

31 (30)

63 (65)

 < 0.001

 History of cardiovascular disease, n (%)

200

18 (17)

49 (50)

 < 0.001

 History of cerebrovascular disease, n (%)

200

3 (3)

18 (19)

 < 0.001

 Diagnosis of dementia, n (%)

200

2 (2)

13 (13)

0.002

 Diagnosis of Cancer, n (%)

200

12 (12)

17 (17)

0.238

 Haematological malignancy, n (%)

200

0 (0)

4 (4)

0.037

 Chronic kidney disease, n (%)

200

2 (2)

14 (14)

0.001

 Dialysis, n (%)

200

0 (0)

3 (3)

0.072

 Chronic liver disease, n (%)

200

1 (1)

6 (6)

0.045

  1. P-values are derived from independent samples Student’s T Test or the Mann Whitney test for continuous variables and the chi squared test for categorical variables; *Median and interquartile range.
Back to article page